Life Sciences

​​​​Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed more than 99,000 people and had sales of EUR 41.4 billion. R&D expenses before special items amounted to EUR 4.9 billion.​Bayer is an international life sciences company that has been operating in Türkiye for nearly 70 years. The company supplies important healthcare and agricultural products to Türkiye. In the last few years, various innovative products that meet the medical and agricultural needs of Türkiye have been put on the market by Bayer. Bayer Pharmaceuticals is among the top 5 in the Turkish pharmaceutical market. In addition to being an important player in women's health, cardiology, ophthalmology, hematology, oncology and pulmonology, Bayer also has a strong position in the field of radiology. The Consumer Health Division ranks second in the OTC market in Türkiye and is the market leader in various key segments. The Crop Science Division offers innovative solutions that create value for the agricultural sector and farmers in Türkiye. The Crop Science Division in Türkiye is active in vegetable seeds, bioscience and environmental science.Bayer Türkiye, which is among the top 20 countries in the world of Bayer, has 1,011 employees as of today and generated sales of EUR 373.8 million for 2020 in Türkiye. With its young and well-educated population, Türkiye is an attractive and long-term resource for global talent. Since Bayer's establishment in Türkiye, over 7,000 people have worked for the company in Türkiye.Bayer's activities in Türkiye are not limited to sales and marketing as Türkiye is an important regional production and development base for Bayer. There are two production facilities for the Crop Science products in Türkiye, one in Gebze, Kocaeli and the other in Mustafa Kemal Paşa, Bursa. In addition, Bayer has an R&D Center in Antalya.Bayer Türkiye has a partnership for the production of Bayer products in Sanofi's production facility in Lüleburgaz, Kırklareli. Within the scope of this partnership, a big step was taken in order to realize the production of an important drug in the cardiology product portfolio in Türkiye in 2020. Bayer plans to make an investment of over EUR 4.5 million. It triples the value-based production volume of the Pharmaceutical Division. With this localization project, the largest such effort in terms of value among cardiology products in Türkiye, Bayer raises the localization percentage of products in the current cardiovascular market to 40 percent.Guided by its purpose of "Science for a Better Life", Bayer carries out many corporate social responsibility (CSR) projects in Türkiye. Bayer Türkiye has brought together more than 41,000 children with science in 10 years with the Bayer Young Science Ambassadors project, realized in cooperation with the Community Volunteers Foundation (TOG).Bayer has evaluated the projects of more than 5,000 students in the Bayer Science Competition for high schools, organized for the seventh time this year, which attracted participation from schools all over Türkiye. In addition to its CSR projects, Bayer has undertaken to support the entrepreneurship ecosystem and has been continuing the G4A Türkiye 2021 project for four years. Within the scope of the project, Bayer contributed TRY 2.5 million to the entrepreneurship ecosystem in the past three years.

​GlaxoSmithKline (GSK) is a focused biopharma company with strong momentum and ambitious goals, bringing together science, technology, and talent to get ahead of disease. With a heritage dating back to the 18th century, GSK is a UK-based company distinguished by its strong portfolio of both conventional and innovative medicines and vaccines. It operates in 75 countries and employs more than 65,000 people.Recognized five times with the Nobel Prize in Medicine for its scientific research and innovative products, GSK invested GBP 6.4 billion in R&D in 2024 and, as a pioneer in healthcare innovation, has approximately 71 drugs and vaccines in development.GSK focuses on the science of the immune system and advanced technologies, investing across four core therapeutic areas, including respiratory, immunology and inflammation, oncology, and HIV and infectious diseases, to deliver impact at scale.As part of its ambition to positively impact the health of 2.5 billion people by the end of 2030 by making its medicines and vaccines as widely accessible as possible, GSK has long supplied polio vaccine to UNICEF.In Türkiye, GSK has been contributing to public health for more than 65 years. Prior to the launch of the Pharmaceutical Product Localization Project in 2016, the company initiated local production of 31 products in collaboration with two local manufacturing partners, enabling the localization of Türkiye’s largest-volume antibiotic portfolio. Following an investment of over GBP 30 million, GSK increased the number of its local manufacturing partners from two to four and plans to further expand its local manufacturing activities in Türkiye.GSK continues to advance its investments in an environment that actively encourages localization within the Turkish pharmaceutical industry. In 2018, the company launched a manufacturing collaboration with a local partner, supported by an investment of GBP 25 million, to transfer the production of nebulizer technology used in respiratory treatment and a patented HIV product to Türkiye.​Through both its healthcare solutions and social responsibility initiatives, GSK has contributed to Türkiye’s future. In collaboration with the Community Volunteers Foundation, GSK reached 4.2 million people between 2018 and 2022 through the “Say Stop at Red!” project, which aimed to raise awareness of rights, especially the rights of children and women to speak up. GSK also provided TRY 1 million in support to those affected by the February 2023 earthquakes and, in October 2023, established a Support Centre in Adıyaman to deliver psychosocial assistance across all earthquake-affected areas, with a special focus on children. In 2025, the Support Centre engaged more than 53,000 participants through over 2,000 organized events.

​​Novartis is a global healthcare company based in Basel, Switzerland, whose mission is to use science-based innovation to address some of society's most challenging healthcare issues. The Novartis Group operates primarily through three divisions that each have a global scale. These divisions are Novartis Pharma, Novartis Oncology and Sandoz.The Novartis Pharma portfolio addresses a wide range of therapeutic areas, including cardiovascular-metabolic, ophthalmology, respiratory, neuroscience, immunology, and dermatology. Novartis Oncology is a leader in driving the practice of precision oncology treatment. Sandoz is a global leader in generic pharmaceuticals and biosimilars, pioneering novel approaches to help people around the world access high-quality medicines. Sandoz has a portfolio of more than 1,000 products covering all major therapeutic areas. Novartis has been committed to Türkiye for more than 60 years. Today, the Novartis Group is locally manufacturing its key products for both Türkiye and export markets. The Group employs more than 2,000 qualified people and has assumed the leading role in the sector with its understanding of creating a people-oriented company culture and the best working place for its employees. In 2019, Novartis Türkiye's total export was USD 136 million. Over the last decade, its exports have exceeded USD 1.6 billion in total. The Novartis Group is also the leading pharma company in clinical research. With more than 100 clinical trials in Türkiye, Novartis Türkiye helps Turkish doctors become more competitive in research globally. The long-term goal of Novartis Türkiye is to continue growing with Türkiye and to assume a pioneering role in further advancing the local pharmaceutical industry with more investment, more R&D, and more output.​

​​​​​​​Currently operating in more than 175 markets with more than 96,000 employees, Pfizer is committed to providing the medical world with innovative products that contribute to human health and quality of life. Founded in the USA in 1849, Pfizer achieved a milestone with the mass production of Penicillin, referred to as the wonder drug, in 1942. In 1951, the company marked its international expansion by founding its businesses in the UK, Cuba, Mexico, and India. With four mergers from 2000 to 2011, Pfizer grew and diversified its portfolio and also increased its power in biotechnology, vaccines, and health products, becoming the world's leading biopharmaceutical company.Pfizer started its operations in Türkiye in 1957, and now produces nearly 75 percent of its total product line in Türkiye with around 1,000 employees. Pfizer has conducted more than 143 clinical trials and has invested more than USD 20 million in Türkiye. So far, more than 3,000 Turkish physicians have undergone training programs provided by Pfizer.Pfizer has an annual R&D budget of over USD 7 billion, making it the leader among pharmaceutical companies when it comes to R&D expenditures. Pfizer carries out over 80 projects in eight research centers across the world, as well as engaging in more than 1,000 ongoing R&D collaborations globally.As part of its commitment to developing pharmaceuticals in Türkiye to improve the country's R&D environment, Pfizer completed numerous projects from 2009 to 2012. The company signed a memorandum of understanding (MoU) with the Republic of Türkiye Prime Ministry Investment Support and Promotion Agency of Türkiye (ISPAT) in 2009 in order to deepen the quality and number of R&D activities in Türkiye and to develop an environment that would support pharmaceutical innovations This led to the opening of the Pfizer R&D office in Hacettepe Technopolis in Ankara. Various programs for fostering pharmaceutical R&D were planned and carried out to bring together researchers from Hacettepe University with Pfizer's global R&D network.In November 2012, Pfizer launched a facility in Türkiye for the production of the pneumococcal conjugate vaccine, one of the most significant biotechnological products in the world. This facility in Türkiye was Pfizer's third such facility in the world at the time (the other two being in the USA and Ireland) where this vaccine would be produced. The vaccine, which is also included in the National Vaccine Calendar of the Turkish Ministry of Health, is referred to as the first vaccine produced in Türkiye starting from the formulation stage with the use of state-of-the-art technologies. The facility, which produced 10 million doses of vaccine as of 2016, has the capacity to meet the vaccine needs of adult risk groups.​Having invested over TRY 8 million in education and health-oriented social responsibility projects over the last decade, Pfizer Türkiye continues to contribute to the welfare of Turkish society. With the launch of the “Get Old Campaign", it aims to raise awareness in individuals about living and aging better, as well as to provide people with the information they need in many areas for a better, healthier, and more fulfilling life. This includes informing on such topics as disease awareness, right lifestyle choices, and protective measures.​​

​World Medicine İlaç Sanayi ve Ticaret Anonim Şirketi was established in Türkiye in 2011 as an affiliate of the World Medicine Corporate Group.World Medicine aims to be a reliable business partner and a leading company in all countries and fields of operation with a diverse portfolio of more than 450 pharmacological products in ophthalmology, neurology, endocrinology, cardiology, rheumatology, gastroenterology, urology, pulmonology, etc.With its headquarters and R&D laboratory equipped with cutting-edge technology in Istanbul, World Medicine exports to more than 35 countries. The company has one of its domestic production facilities in Istanbul and the other in Tekirdağ, Çerkezköy. The company also has two overseas production facilities in Romania and Algeria.World Medicine's success story started by earning the ninth-place award in "Export of Pharmaceutical Products" category in 2016. The company maintained its winning streak in 2017 with the "Fastest Rising Company in Export" award and a third-place award in "Export of Pharmaceutical Products" category. It later walked away with the third-place award in the “Stars of Export" category in 2018. With its successful export performance in 2019, World Medicine ended in the second place in the "Stars of Export - Pharmaceutical Exports" category of the Istanbul Chemicals and Chemical Products Exporters' Association (IKMIB). Thanks to its export record in 2020, it was named Türkiye's leading pharmaceutical exporter.World Medicine ranked 390th on the ISO 500 list in 2021, leaving behind many pharmaceutical companies that had previously been on this list and ranked 5th in the industries.In addition to factory investments, the company focuses on R&D operations and aligns itself with innovative technologies with the aim of becoming a prominent company in the global R&D market.World Medicine ranks among the “R&D 250, Türkiye's Top R&D Spending Companies" list and continues to grow rapidly. According to 2022 results, World Medicine was the 2nd company in the list of companies that carry out the most projects among all industries across Türkiye. Likewise, it ranked first in the pharmaceutical industry.World Medicine continues to expand with over 1,500 employees who are all experts in their fields, proudly representing Türkiye around the world.​